GASTRIC CANCER

This early-phase study tested a new drug called CUE-102 in 42 adults with advanced colorectal, gastric, pancreatic, or ovarian cancers that had stopped responding to standard treatments. Participants had a specific genetic marker (HLA-A*0201) and their tumors produced a protein c…

This study tested a new combination of two drugs, GEN-001 and avelumab, in 42 people with advanced stomach or gastroesophageal junction cancer that had not responded to at least two prior treatments. Participants had a specific marker (PD-L1 positive) and had not received immunot…

This study tested a new computer-based tool to help doctors adjust chemotherapy doses for people with cancers of the digestive system (like colorectal or stomach cancer). The goal was to reduce unplanned delays in treatment while keeping the dose strong enough to fight the cancer…

This study tested a combination of two drugs, TAS 102 and ramucirumab, in 23 people with advanced stomach or gastroesophageal junction cancer that had stopped responding to prior treatments. The goal was to see if the combination was safe and could help patients live longer. The …

This early-phase study tested a new treatment called VE800, made from live bacteria, combined with the immunotherapy drug nivolumab in 56 people with advanced or metastatic cancers like melanoma, stomach, and colorectal cancer. The main goals were to check safety and see if tumor…

This study tested a combination of two drugs—telatinib and Keytruda—in 16 people with advanced stomach or liver cancer that had not responded to prior treatments. The goal was to see if the combo could slow cancer growth or improve survival. Participants received both drugs and w…

This study tested a new treatment for stomach cancer that has spread to the lining of the abdomen. It combines standard chemotherapy given through a vein with a special pressurized spray of chemo directly into the abdomen during a short procedure. The goal was to see if this comb…

This study tested whether adding the drug pembrolizumab to standard chemotherapy helps Chinese adults with stomach or gastroesophageal junction cancer. Participants received the drug or a placebo before and after surgery. The goal was to see if the combination improves outcomes l…

This early-stage study tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, or lung cancer) that had stopped responding to standard treatments. The drug is a nanoparticle version of a chemotherapy agent, given through an IV, and the m…

This early study tested a new drug called Cabotamig (ARB202) in 33 adults with advanced gastrointestinal cancers (like stomach, liver, or bowel cancer) that had stopped responding to standard treatments. The drug works by targeting a marker called CDH17 on cancer cells and helpin…

This study tested a combination of chemotherapy (CAPOX) and two targeted antibodies (trastuzumab and bevacizumab) in 37 adults with HER2-positive metastatic stomach or esophageal cancer. The goal was to see how well the treatment shrank tumors and how safe it was. Results showed …

This study tested a trastuzumab biosimilar (a copy of the original drug) in 8 people with advanced or recurrent HER2-positive stomach cancer. The goal was to confirm the drug's safety and how well it works in real-world use. Researchers tracked side effects and tumor shrinkage us…

This study tested a combination of two drugs, lenvatinib and pembrolizumab, in 611 people with advanced solid tumors including breast, ovarian, stomach, colorectal, brain, bile duct, and pancreatic cancers that had stopped responding to standard treatments. The goal was to see if…

This study tested a new drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, breast, or colon cancer) that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was completed, …

This study tested a new drug (FLX475) combined with an immunotherapy (pembrolizumab) in 20 people with advanced or metastatic stomach cancer. The goal was to see if the combination could shrink tumors. Participants had already tried other treatments without success. The study is …

This study tested a combination of drugs (camrelizumab, chemotherapy, and apatinib) as a first treatment for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal was to see if this combo helps people live longer compared to …

This study tested a drug called savolitinib in 110 people with advanced stomach or esophagus-stomach junction cancer whose tumors have a specific gene change (MET amplification). The goal was to see if the drug could shrink tumors and how safe it was. Participants took the drug b…

This study tested a new drug called SAR444245 combined with other cancer treatments in 138 adults with advanced gastrointestinal cancers, including esophageal, stomach, liver, and colorectal cancer. The goal was to see if the combination could shrink tumors. The study is complete…

This study tested whether a longer intestinal bypass during stomach cancer surgery improves diabetes control more than the standard approach. It involved 94 adults with early-stage gastric cancer and type 2 diabetes. The goal was to see if the new method could lower blood sugar a…

This early-phase study tested an experimental drug called SHR-A1811 in 101 people with advanced stomach or colorectal cancers that have a specific protein (HER2). The main goals were to check safety, find the right dose, and see if the drug can shrink tumors. Participants had can…

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with stomach or gastroesophageal junction cancer. Over 1,000 adults received either the drug combo or chemo alone before and after surgery. The goal was to see if the combi…

This study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (stomach cancer, liver cancer, or other types) that had stopped responding to standard treatments. The drug was given by IV every two weeks for up to 12 doses, with the option to continue if pa…

This study looked at whether a specific chemotherapy regimen (FOLFIRI) plus radiation is practical for stomach cancer patients. 63 people with non-spreading stomach cancer received the treatment either before or after surgery. The goal was to see if this approach is feasible and …

This study tested a combination of two drugs, crizotinib (a tablet) and fulvestrant (an injection), in 33 people with advanced lobular breast cancer that is estrogen-receptor positive. It also tested crizotinib alone in people with diffuse gastric cancer, triple-negative lobular …

This early-phase study tested a new treatment using specially engineered immune cells (CAR-NK cells) from donated cord blood to target a protein called Claudin18.2 found on some stomach and pancreatic cancer cells. Ten adults with advanced cancer who had no other treatment option…

This study tested a new PET imaging agent called [18F]FAPI-74 in 109 people with gastrointestinal cancers, including liver, bile duct, stomach, pancreas, and colorectal cancers. The goal was to see if the scan could accurately find cancer cells by targeting a protein called FAP. …

This study tested a training program for doctors to use a special microscope called confocal laser endomicroscopy (CLE) during a stomach exam. The goal was to see if the training helps doctors more accurately identify cancerous or pre-cancerous spots in the stomach. 147 adults to…

This study looked at how a type of PET/CT scan (using 18F-FDG) can help doctors more accurately diagnose, stage, and track stomach cancer. Researchers studied 50 patients with confirmed stomach cancer to see if the scan could find tumors and check how well treatment is working. T…

This study tested a new type of PET scan (FAPI) in 20 people with stomach or gastro-esophageal junction cancer to see if it can more accurately determine the cancer stage than standard scans. Participants received the FAPI scan alongside usual imaging before and after chemotherap…

This study compared two surgical methods for stomach cancer: laparoscopic (keyhole) surgery and open surgery. The goal was to see if keyhole surgery leads to a shorter hospital stay and fewer complications. 210 adults with resectable stomach cancer took part. Results will help do…

This study tested over 1,000 people in Bhutan for H. pylori infection and stomach cancer risk using blood tests and endoscopy. The goal was to gather baseline data to help launch a national stomach cancer prevention program. Participants were permanent residents aged 12 and older…

This study tested a scoring model that doctors can use before surgery to predict whether stomach cancer has spread to nearby lymph nodes. Researchers checked the model in 120 patients who had surgery for stomach cancer. The goal was to see if the model works well in real-world se…

This study tested a new automated method to grow cancer cells from patients inside chicken eggs. Researchers used samples from 101 people with metastatic cancers like prostate, breast, and lung cancer. The goal was to see if the automated system could successfully grow tumors at …

This study follows over 32,900 adults from Linxian, China, a region with very high rates of esophageal and stomach cancer. Researchers are tracking cancer cases and deaths years after participants took vitamin and mineral supplements in the 1980s. The goal is to see if the earlie…

This study looked at people with advanced solid tumors (like lung, bladder, or skin cancer) who had been on immunotherapy (PD-1/PD-L1 inhibitors) for one year and whose disease was stable. It randomly assigned them to either stop treatment or continue until their cancer got worse…

This study tested whether a special DNA test (epigenetics multi-omics sequencing) can predict how well immunotherapy works for people with stomach or rectal cancer. 189 patients took part. The goal was to see if the test could tell who would have a complete response to treatment.…

This study looked back at medical records of 260 adults in China with advanced stomach or gastroesophageal junction cancer. All patients received nivolumab as their first treatment. The goal was to see how well the drug worked in real life and how it was used. This was an observa…

This study tested a risk scoring model to predict if stomach cancer will spread to the liver after surgery. Researchers followed 120 patients who had their stomach cancer removed to see how well the model worked. The goal is to help doctors identify high-risk patients and plan be…